SEARCH

SEARCH BY CITATION

References

  • 1
  • 2
    Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and Worldwide. Skin Pharmacol Physiol 2001: 14: 280290.
  • 3
  • 4
  • 5
  • 6
    MacKie R, Bray C, Vestry J et al. Melanoma incidence and mortality in Scotland 1979–2003. Br J Cancer 2007: 96: 17721777.
  • 7
    Middleton M R, Grob J J, Aaronson N et al. Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 2000: 18: 158166.
  • 8
    Bedikian A, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006: 24: 47384745.
  • 9
    Chapman P B, Einhorn L H, Meyers M L et al. Phase III multicentre randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999: 17: 27452751.
  • 10
    Middleton M, Lorigan P, Owen J et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000: 82: 11581162.
  • 11
    Atkins M B, Lotze M T, Dutcher J P et al. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999: 17: 21052116.
  • 12
    Agarwala S S, Glaspy J, O’Day S J et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002: 20: 125133.
  • 13
    Bajetta E, Del Vecchio M, Nova P et al. Multicentre phase III randomised trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha-2b in metastatic melanoma patients. Ann Oncol, 2006: 17: 571577.
  • 14
    Keilholz U, Punt C J, Gore M et al. Dacarbazine, cisplatin and interferon--alpha-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005: 23: 67476755.
  • 15
    Atkins M B, Lee S, Flaherty L E et al. A prospective randomised phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. J Clin Oncol 2003: 22 (abstract 2847).
  • 16
    Eigentler T, Caroli U, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003: 4: 748759.
  • 17
    Ives N, Stowe R, Lorigan P, Wheatley K. Meta-analysis of chemotherapy and biochemotherapy in metastatic malignant melanoma. J Clin Oncol 2007: 25: 34263434.
  • 18
    Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicentre phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990: 66: 18731878.
  • 19
    Avril M, Grob J, Hauschild A et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma. J Clin Oncol 2004: 22: 11181125.
  • 20
    Lee S M, Thatcher N, Crowther D, Margison G P. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994: 69: 452456.
  • 21
    Su Y B, Sohn S, Krown S E et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004: 22: 610616.
  • 22
    Stupp R, Mason W P, Van Den Bent M J et al. Radiotherapy plus concomitant and adjuvant temozolomide and for glioblastoma. N Engl J Med 2005: 352: 987996.
  • 23
    Agarwala S S, Kirkwood J M, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004: 22: 21012107.
  • 24
    Middleton M R, Lee S M, Arance A et al. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000: 88: 469473.
  • 25
    Dolan M E, Posner M, Karrison T et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically respectable tumours. Clin Cancer Res 2002: 8: 25192523.
  • 26
    Ranson M, Hersey P, Thompson D et al. Randomised trial of combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007: 25: 25402454.
  • 27
    Plummer R, Lorigan P, Evans J et al. First and final report of a phase II study of the PARP inhibitor AGO14699 in combination with temozolomide in patients with metastatic melanoma. J Clin Oncol 2006: 24: 8013.
  • 28
    Tang L, Tron V, Reed J et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998: 4: 18651871.
  • 29
    Bush J, Li G. The role of the Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003: 20: 531539.
  • 30
    Hu Y, Cherton-Horvat G, Dragowska V et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003: 9: 28262836.
  • 31
    Gonzalez R, Lewis K, Samlowski W et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or IV melanoma. J Clin Oncol 2007: 25: 8538.
  • 32
    Sosman J, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006: 12 (Suppl. 7): 23762383s.
  • 33
    Panka D, Atkins M, Mier J. Targeting of mitogen-activated protein kinase pathways in the treatment of malignant melanoma. Clin Cancer Res 2006: 12 (Suppl. 7): 23712375.
  • 34
    Davies H, Bignell G R, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002: 417: 949954.
  • 35
    Garnett M J, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004: 6: 313319.
  • 36
    Wan P T, Garnett M J et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004: 116: 855867.
  • 37
    Sharma A, Trivedi N R et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005: 65: 24122421.
  • 38
    Gollob J A, Wilhelm S et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal of transduction pathway. Semin Oncol 2006: 33: 392406.
  • 39
    Eisen T, Ahmad T et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006: 95: 581586.
  • 40
    Amaravadi R, Schuchter L, McDermott D et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 2007: 25: 8527.
  • 41
    Agarwala S, Keilholz U, Hogg D et al. Randomised Phase III trial of paclitaxel + carboplatin with or without sorafenib in patients with advanced melanoma. J Clin Oncol 2007: 25: 8510.
  • 42
    Lev D C, Onn A et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004: 22: 20922100.
  • 43
    Lev D C, Ruiz M et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003: 2: 753763.
  • 44
    Eisen T, Ahmad T, Gore M E et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J Clin Oncol 2005: 23: 7508.
  • 45
    Eisen T, Marais R, Affolter A et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol 2007: 25: 8529.
  • 46
    McDermott D, Sosman J, Hodi F et al. Randomised phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J Clin Oncol 2007: 25: 8511.
  • 47
    Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007: 356: 22712281.
  • 48
    Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005: 104: 10451048.
  • 49
    Curtin J, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006: 24: 434035.
  • 50
    Wyman K, Atkins M, Prieto V et al. A multi-centre phase II trial of high dose imatinib in metastatic melanoma: significant toxicity with no clinical activity. Cancer 2006: 106: 20052011.
  • 51
    Wyman K, Kelley M, Puzanov I et al. Phase II study of erlotinib given daily for patients with melanoma. J Clin Oncol 2007: 25: 18002.
  • 52
    Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of cell division. Cell Death Differ 2005: 12: 11911197.
  • 53
    Kashani-Sabet M, Shaikh L, Miller J et al. NF-kB in the vascular progression of melanoma. J Clin Oncol 2004: 22: 617623.
  • 54
    Mani A, Gelmann E. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005: 23: 47764789.
  • 55
    Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004: 4: 349360.
  • 56
    Markovic S N, Geyer S M, Dawkins F et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005: 103: 25842589.
  • 57
    Kefford R, Milward M, Hersey P et al. Phase II trial of tanespimycin (KOS-953), a Hsp90 inhibitor in patients with metastatic malignant melanoma. J Clin Oncol 2007: 25: 8558.
  • 58
    Sigalotti L, Fratta E, Coral S et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007: 212: 330344.
  • 59
    Das P M, Singal R. DNA methylation and cancer. J Clin Oncol 2004: 22: 46324642.
  • 60
    Laird P W. Cancer epigenetics. Hum Mol Genet 2005: 14: R65R76.
  • 61
    Stromblad S, Becker J C, Yebra M, Brooks P C, Cheresh D A. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996: 98: 426433.
  • 62
    Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003: 22: 30923098.
  • 63
    Hauschild A, Trefzer U, Garbe C et al. A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. J Clin Oncol 2006: 24: 8044.
  • 64
    Gollob J, Sciambi C, Peterson B et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006: 12: 46194627.
  • 65
    O’Day S, Gonzalez R, Lawson D et al. Subgroup analysis of efficacy and safety analysis of a randomised, double blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. J Clin Oncol 2007: 25: 8528.
  • 66
    Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000: 14: 1720.
  • 67
    Danson S, Lorigan P, Arance A et al. A randomised study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). J Clin Oncol 2003: 21: 25512557.
  • 68
    Hwu W J, Krown S E, Menell J H et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003: 21: 33513356.
  • 69
    Bartlett J B, Michael A, Clarke I A et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of the thalidomide analogue CC-5013 in patients with metastatic melanoma and other advanced cancers. Br J Cancer 2004: 90: 955961.
  • 70
    Bedikian A, Kim K, Papadopoulos N et al. Preliminary results from a phase II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy. J Clin Oncol 2007: 25: 8533.
  • 71
    Mouawad R, Soubrane C, Khayat D et al. Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A, C, D) and their receptors (R1, R2, and R3) in advanced melanoma. J Clin Oncol 2007: 25: 8540.
  • 72
    Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal carcinoma. N Engl J Med 2004: 350: 23352342.
  • 73
    Sandler A, Gray R, Perry M et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006: 355: 25422550.
  • 74
    Varker A, Biber J, Kefauver C et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007: 14: 23672376.
  • 75
    Wyman K, Spigel D, Puzanov I et al. A multicentre phase II trial of erlotinib and bevacizumab in patients with malignant melanoma. J Clin Oncol 2007: 25: 8539.
  • 76
    Perez D, Suman V, Amatruda T et al. Phase II trial of carboplatin, weekly paclitaxel and biweekly bevacizumab in patients with unresectable stage IV melanoma. J Clin Oncol 2007: 25: 8560.
  • 77
    McNeel D, Eickoff J, Lee F et al. Phase I trial of a monoclonal antibody specific for αVβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effects on tissue perfusion. Clin Cancer Res 2005: 11: 78517860.
  • 78
    Kim K, Diwan A, Papadopoulos A et al. A randomised phase II study of EMD 121974 in patients with metastatic melanoma. J Clin Oncol 2007: 25: 8548.
  • 79
    Mullamitha S, Ton C, Parker G et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumours. Clin Cancer Res 2007: 13: 21282135.
  • 80
    O’Day S, Richards J, Jiao T et al. Phase I/II study of CNTO95, a fully human monoclonal antibody to alpha-c integrin in patients with metastatic melanoma. Eur J Cancer (Suppl) 2006: 4: 218.
  • 81
    Peterson A C, Swiger S, Stadler W M et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004: 10: 40484054.
  • 82
    Soiffer R, Hodi F S, Haluska F et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003: 21: 33433350.
  • 83
    Hawkins R, Keilholz U, Dangoor A et al. Evaluation of a novel heterologous prime boost immunotherapy in stage III/IV metastatic melanoma patients. J Clin Oncol 2005: 23 (abstract 2570).
  • 84
    Smith C M, Wilson N S, Waithman J et al. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nat Immunol 2004: 11: 11431148.
  • 85
    Richards J, Testori A, Whitman G et al. Autologous tumor-derived HSPPC-96 vs. physician’s choice (PC) in a randomized phase III trial in stage IV melanoma. J Clin Oncol 2006: 23: 8002.
  • 86
    Morton D, Mozzillo N, Thompson J et al. An international, randomised, phase III trial of BCG plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional nodes or distant sites. J Clin Oncol 2007: 25: 8508.
  • 87
    Eggermont A, Gore M. Randomised adjuvant trials in melanoma: surgical and systemic. Semin Oncol 2007: 34: 509515.
  • 88
    Grabbe S, Beissert S, Schwarz T, Granstein R D. Dendritic cells as initiators of tumour immune responses: a possible strategy for tumour immunotherapy? Immunol Today 1995: 16: 117121.
  • 89
    Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC Study Group of the DeCOG. Ann Oncol 2006: 17: 563570.
  • 90
    Attia P, Phan G, Maker A et al. Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005: 23: 60436053.
  • 91
    Downey S, Klapper J, Smith F et al. Prognostic factors related to clinical response in patients with metastatic malignant melanoma treated by CTL-Associated Antigen-4 blockade. Clin Cancer Research 2007: 13: 66816688.
  • 92
    Ribas A, Camacho L H, Lopez-Berestein G et al. Antitumour activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005: 23: 89688977.
  • 93
    Bulanhague C, Ribas A, Pavlov D et al. Phase I clinical trial of ticilimumab: tumour responses are sufficient but not necessary for prolonged survival. J Clin Oncol 2006: 24: 8036.
  • 94
    Maker A, Attia P, Rosenberg S. Analysis of the cellular mechanism of antitumour response and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005: 175: 77467754.
  • 95
    Butte M, Keir M, Phamuduy T et al. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses. Immunity 2007: 27: 111122.
  • 96
    Dong H, Strome S, Salomao D et al. Tumour associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002: 8: 793800.
  • 97
    Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma nodes and inhibit the function of infiltrating T cells. J Immunol 2004: 173: 14441453.
  • 98
    Chattopadhyay S, Mehrotra S, Chhabra A et al. Effect of CD4+CD25+ and CD4+CD25 T-regulator cells on the generation of cytolytic T-cell response to a self but human tumour-associated epitope in vitro. J Immunol 2006: 176: 984990.
  • 99
    Cesana G, DeRaffele G, Cohen S et al. Characterisation of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006: 24: 11691177.
  • 100
    Ahmadzadeh M, Rosenberg S. Il-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood 2006: 107: 24092414.
  • 101
    Buhaescu I, Segall L, Goldsmith D et al. New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrology 2005: 18: 529536.
  • 102
    Litzinger M, Fernando R, Curiel T, et al. The IL-2 immunotoxin denileukin diftitoxin (Ontak) reduces regulatory T cells and enhances vaccine mediated T-cell immunity. Blood 2007: 110: 31923201.
  • 103
    Dang N, Fayad L, Mclaughlin P et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Cancer 2007: 138: 502505.
  • 104
    Dang N, Pro B, Hagenmeister F et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell nonHodgkins lymphoma. Br J Cancer 2007: 136: 439447.
  • 105
    Attiua P, Maker A, Haworth L et al. Inability of fusion protein of IL-2 and dipteria toxin (Denileukin Diftitix, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005: 28: 582592.
  • 106
    Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumour immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005: 115: 36233633.
  • 107
    Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony stimulating factor based antitumour vaccine. J Clin Oncol 2007: 25: 25462553.
  • 108
    Eggermont A, Suciu S, Santinami M et al. EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma’ final results of a randomised phase III trial. J Clin Oncol 2007: 25: 8504.
  • 109
    Drummer R, Garbe C, Thompson J et al. Randomised dose escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006: 24: 11881194.
  • 110
    Pelusi I, Fantini M, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of Human CD4+ T Lymphocytes. J Immunol 2007: 178: 732739.
  • 111
    Davis I D, Skrumsager B K, Cebon J et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007: 13: 36303636.
  • 112
    Gollob J, Mier J, Veenstra K et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000: 6: 16781692.
  • 113
    Atkins M, Robertson M, Gordon M et al. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin Cancer Res 1997: 3: 409417.
  • 114
    Cebon J, Jager E, Shackleton M et al. Two phase I studies of low dose recombinant IL-12 with Melan-A and influenza peptides in subjects with advanced melanoma. Cancer Immunol 2003: 3: 7.
  • 115
    Peterson A, Harlin H, Gajewski T et al. Immunisation with Melan-A peptide pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003: 21: 23422348.
  • 116
    Hamid O, Solomon J, Scotland R et al. Alum with Interleukin-12 augments immunity to a melanoma peptide vaccine; correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007: 13: 215222.
  • 117
    Sjogren M. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 2004: 19: S69S72.
  • 118
    Inio S, Toyota J, Kumada H et al. The safety and efficacy of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomised clinical trial. J Viral Hepat 2005: 12: 300306.
  • 119
    Camerini R, Mackiewicz A, Testori A et al. A first-line, randomised, dose finding, phase II study on thymosin alpha-1 plus DTIC without or without IFN-alpha compared to DTIC + IFN in patients with stage IV melanoma. J Clin Oncol 2007: 25: 8385.
  • 120
    Schneeberger A, Wagner C, Zemann A et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004: 123: 371379.
  • 121
    Pashenkov M, Goess G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006: 24: 57165724.
  • 122
    Harrison L I, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007: 47: 962969.
  • 123
    Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signalling in the haemopoietic system elicits muticomponent antitumour activity. Nat Med 2005: 11: 13141321.
  • 124
    Mackensen A, Meidenbauer N, Vogl S et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8 T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006: 24: 50605069.
  • 125
    Dudley M E, Wunderlich J R, Yang J C et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005: 23: 23462357.